The Technical Analyst
Brainstorm Cell [BCLI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Brainstorm Cell Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
3.44% $0.532
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 36.36 mill |
| EPS: | -0.400 |
| P/E: | -1.330 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 68.34 mill |
| Avg Daily Volume: | 1.013 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.330 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.23x |
| Company: PE -1.330 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0006 (-99.89%) $-0.531 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.440 - 0.624 ( +/- 17.29%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-18 | Lebovits Chaim | Buy | 115 072 | Common Stock |
| 2024-04-17 | Lebovits Chaim | Buy | 130 000 | Common Stock |
| 2024-03-11 | Lindborg Stacy | Buy | 241 935 | Common Stock |
| 2024-03-11 | Yablonka Uri | Buy | 109 426 | Common Stock |
| 2024-03-11 | Patlis Alla | Buy | 65 246 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 91 transactions |
| Buy: 3 104 128 | Sell: 254 714 |
Forecast:
16:00 - $0.538
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.538
Forecast 2: 16:00 - $0.538
Forecast 3: 16:00 - $0.538
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.532 (3.44% ) |
| Volume | 0.997 mill |
| Avg. Vol. | 1.013 mill |
| % of Avg. Vol | 98.40 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BCLI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | buy | $0.394 | N/A | Active |
|---|
BCLI
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Latest Press Releases
2024-04-16 18:30:00 - Press Release
Brainstorm Cell Therapeutics Announces Management Changes As Company Plans Registrational Phase 3b Trial Of Nurown
Bob dagher, md, promoted to chief medical officer dr. stacy lindborg stepping down as co-ceo and transitioning to board of directors new york , april 16, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of dr. bob dagher to executive vice president and chief medical officer. in addition, after four years of maintaining top executive roles, dr. stacy lindborg stepping down from the role of co-ceo and will remain with brainstorm as a member of its board of directors.
2024-04-11 06:00:00 - Press Release
Brainstorm Cell Therapeutics Regains Compliance With Nasdaq Minimum Market Value Rule
New york , april 11, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli, "the company"), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it received a notification letter (the "notification letter on compliance") on april 10, 2024 from the listing qualifications department of the nasdaq stock market ("nasdaq"), indicating that the company has regained compliance with the minimum market value of listed securities requirement set forth under nasdaq listing rule 5550(b)(2) (the "rule"). according to the notification letter on compliance, nasdaq's staff has determined that for the 11 consecutive business days, from march 22, 2024 through april 9, 2024, the company's market value of listed securities has been $35,000,000 or greater, and the company has regained compliance with the rule.
2024-04-10 06:00:00 - Press Release
Brainstorm Cell Therapeutics Announces Peer-reviewed Publication Of Biomarker Data From Nurown's® Phase 3 Clinical Trial In Als
Nurown treatment resulted in a positive impact on important csf biomarkers relevant to als compared to placebo.significant changes in multiple als disease pathways support nurown's mechanism of action and complement clinical effects observed in als. new york , april 10, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer-reviewed publication of phase 3 biomarker data in muscle and nerve.
2024-04-09 06:00:00 - Press Release
Brainstorm Cell Therapeutics Announces Agreement With Fda On A Special Protocol Assessment (spa) For Phase 3b Trial In Als
Conference call and webcast at 8:00 a.m. eastern time today new york , april 9, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the u.s. food and drug administration (fda), under a special protocol assessment (spa), on the design for a phase 3b trial of nurown® in amyotrophic lateral sclerosis (als).
2024-04-08 06:00:00 - Press Release
Brainstorm Cell Therapeutics To Provide Update On Nurown Program
A conference call and webcast will be held tomorrow, april 9, at 8:00 a.m. eastern time new york , april 8, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on the nurown® program tomorrow, april 9, at 8:00 am eastern time.
Latest News
2024-02-13 06:30:00 - PRNewsWire
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
NEW YORK , Feb. 13, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will provide a corporate update at the 17th Annual European Life Sciences CEO Forum to take place 28 - 29 of February, 2024 in Zurich, Switzerland. Presentation Details Presentation Date: Wednesday, 28th FebruaryTime: 13:40h CETLocation: Panorama Room (Track C), Hilton Zurich Airport Hotel Dr. Stacy Lindborg, Co-CEO of BrainStorm, will also participate in a panel discussion Neuro Advances Panel: Highlighting the Main Opportunities, at 17:20h on February 28.
2023-11-17 07:00:00 - PRNewsWire
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia
Presentation on NurOwn Phase 3 data demonstrating evidence of biological effect in ALS; Biomarker data reinforce clinical outcomes NEW YORK , Nov. 17, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE. The presentation will feature new analyses from the NurOwn placebo-controlled Phase 3 amyotrophic lateral sclerosis (ALS) trial that highlight the biological effect of NurOwn through CSF biomarker data.
2023-11-14 12:20:09 - Seeking Alpha
BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2023 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 8:58 AM ET BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q3 2023 Earnings Conference Call November 14, 2023, 08:30 AM ET Company Participants Chaim Lebovits - President and CEO Stacy Lindborg - Co-CEO Alla Patlis - Interim CFO Michael Wood - LifeSci Advisors Conference Call Participants David Bautz - Zacks Small-Cap Research Operator Greetings, and welcome to the BrainStorm Cell Therapeutics Third Quarter 2023 Earnings Call. At this time, participants are in a listen-only mode.
2023-09-28 09:46:07 - Proactive Investors
BrainStorm shares plunge 56% after FDA advisers reject ALS cell therapy
Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) plummeted by 56% in early trading after the company's treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, received the red light from advisors to the US Food and Drug Administration (FDA). The Cellular, Tissue, and Gene Therapies Advisory Committee voted 17 to 1, with one abstention, against the efficacy of BrainStorm's cell therapy, NurOwn.
2023-09-28 08:00:00 - Market Watch
Brainstorm Cell Therapeutics shares fall more than 50% after FDA advisors vote down ALS treatment
BrainStorm Cell Therapeutics Inc. BCLI, -8.35% shares fell 56% premarket on Thursday after advisors to the U.S. Food and Drug Administration on Wednesday gave a thumbs-down to the company's investigational treatment for amyotrophic lateral sclerosis (ALS). The FDA advisors voted that the treatment, the mesenchymal stem cell therapy NurOwn, did not demonstrate substantial evidence of effectiveness for treatment of mild to moderate ALS.
2023-09-27 19:36:00 - Market Watch
FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics
A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics BCLI, -8.35% for amyotrophic lateral sclerosis, or ALS.
2023-09-27 18:10:39 - Reuters
US FDA panel votes against BrainStorm's ALS therapy
The U.S. health regulator's advisers on Wednesday voted against BrainStorm Cell Therapeutics' therapy for patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease.
2023-09-25 11:28:05 - Proactive Investors
BrainStorm Cell shares fall as FDA reviewers raise doubts over effectiveness of ASL therapy
Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell almost 40% on Monday morning after Food and Drug Administration (FDA) staff reviewers expressed doubts over the safety and efficacy of the biotech's therapy NurOwn for neurogenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. Brainstorm's NurOwn is being reviewed by the FDA's Cellular, Tissue and Gene Therapies Advisory Committee on Wednesday, September 2023.
2023-09-25 08:38:38 - Reuters
FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy
The U.S. Food and Drug Administration's staff reviewers raised concerns on Monday over the safety and efficacy of BrainStorm Cell Therapeutics' amyotrophic lateral sclerosis (ALS) therapy, sending the company's shares down 50% in premarket trading.
2023-09-15 18:03:07 - Seeking Alpha
Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks
BCLI has completed a phase 3 trial in ALS. Despite not meeting the primary endpoint BCLI is still applying for approval and an AdCom meeting is scheduled for September 27. NurOwn was significantly better than placebo in the pre-specified subgroup of patients with earlier-stage ALS as well as in post-hoc analyses accounting for the "floor effect". Supportive biomarker data and Fast Track designation mean potential for accelerated approval (similar to the recently approved tofersen, which also did not meet the primary endpoint in its phase 3).